FDA Approves Nucleus Hybrid L24 Cochlear Implant System

by Kathy Jones on  March 21, 2014 at 7:52 PM General Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

Australian biotechnology company Cochlear Ltd revealed that it has secured approval from the US Food and Drug Administration to sell its Nucleus Hybrid L24 Cochlear Implant System in the American market.
 FDA Approves Nucleus Hybrid L24 Cochlear Implant System
FDA Approves Nucleus Hybrid L24 Cochlear Implant System

According to Cochlear, the new implant will help improve hearing in patients who are able to hear low frequency sounds without the help of any hearing aid but suffer from hearing loss in high frequencies.

The device works by using electrical stimulation for high frequencies and acoustic amplification for low frequencies, the company said.

Stating that the device will provide new treatment options for people suffering from this type of hearing loss, FDA's Christy Foreman said, "Hearing loss greatly impacts the education, employment, and well-being of many Americans. This device may provide improved speech recognition for people with this kind of hearing loss, who have limited treatment options."


Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Presbycusis Hearing Aids Auditory Tumor Hearing Loss in Young Children and Early Intervention Cochlear Implants 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...